Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20981799 | 0.79 | CA2 (0.50) | CA2ENPP2LMNARECQLCYP3A4 | |
| SCHEMBL16016897 | 0.79 | MGLL (0.52) | MGLLALDH1A1CHRNA7 | |
| SCHEMBL15018285 | 0.78 | TUBB4A (0.39) | CA2MGLLCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15023901 | 0.78 | FGFR1 (0.42) | MGLL | |
| SCHEMBL22132828 | 0.77 | ERN1 (0.38) | MGLLENPP2ALDH1A1KDM4EHPGD | |
| SCHEMBL30638470 | 0.77 | MGLL (0.53) | CA2MGLLALDH1A1KMT2A | |
| SCHEMBL28660108 | 0.77 | MGLL (0.53) | CA2MGLLALDH1A1KMT2A | |
| SCHEMBL594128 | 0.75 | MGLL (0.52) | MGLLCHRNA7 | |
| SCHEMBL16010451 | 0.75 | CYP3A4 (0.37) | MGLLLMNACYP3A4ALDH1A1KDM4E | |
| SCHEMBL29957801 | 0.75 | HDAC3 (0.54) | CA2MGLLENPP2CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3670513-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-06-24 | — | — | EP | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| WO-2013087578-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087647-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20040030131-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-6265575-B1 | THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6251921-B1 | ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, FGFR1, FGFR3 | CA2 2759/4885MGLL 4861/4885ENPP2 4671/4885 |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | CA2 1206/4885MGLL 4539/4885ENPP2 4751/4885 |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | STK25, CDK5, JAK2 | CA2 3661/4885MGLL 4774/4885ENPP2 1923/4885 |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | FGFR1, FGFR2, FGFR3 | CA2 1324/4885MGLL 2838/4885ENPP2 4250/4885 |
| US-20040030131-A1 | Pharmaceutical compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PYM1, CHRM1 | CA2 1695/4885MGLL 3823/4885ENPP2 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.